Log on / register
Feedback | Support | My details
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
Liu-Seifert H, Adams DH, Kinon BJ
BMC Med 2005, 3:21
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Research    
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
Faries DE, Nyhuis AW, Ascher-Svanum H
Cost Effectiveness and Resource Allocation 2009, 7:11 (27 May 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
2.


Research    
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD
Cost Effectiveness and Resource Allocation 2009, 7:4 (7 April 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
3.


Research article    
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
Stauffer V, Ascher-Svanum H, Liu L, Ball T, Conley R
BMC Psychiatry 2009, 9:13 (31 March 2009)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
4.


Research article    
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J
BMC Psychiatry 2006, 6:8 (21 February 2006)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

This article is also cited by a further 5 articles in PubMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.